Possible New Discovery in Lung Cancer Research

  • The majority of cancer deaths are from non-small cell lung cancer, and such malignant tumors are vey difficult to treat.
  • The Russian scientists have discovered a group of proteins involved in the body's natural defense against this cancer.
  • It is expected to be completed prior to 2030.

Russian scientists from the Center for High Precision Editing and Genetic Technologies for Biomedicine announced the start of work pertaining the previous findings of the substances that prevent the growth of the most dangerous malignant tumors. It could lead to a new treatment for lung cancer.

Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. The vast majority (85%) of cases of lung cancer are due to long-term tobacco smoking.

The Center for High Precision Editing and Genetic Technologies for Biomedicine combines the V. A. Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, the Institute of Gene Biology of the Russian Academy of Sciences, and RNIMU. Pirogov Ministry of Health of Russia, and the Federal Scientific-Clinical Center of Physico-Chemical Medicine FMBA of Russia.

The majority of cancer deaths are from non-small cell lung cancer, and such malignant tumors are vey difficult to treat. Another type of a very aggressive type of cancer is glioblastoma. Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells.

The Russian scientists have discovered a group of proteins involved in the body’s natural defense against this cancer. By studying the functioning of these proteins in more detail, scientists will be able to create new strategies for cancer treatment.

The research work titled “Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer,” was published at the end of last year. However the advanced work on the findings just started.

Russian President Vladimir Putin was briefed on the new cancer research strategy in May. It involves utilization of the CTDSP1, CTDSP2 and CTDSPL phosphatases. They are involved in many vital processes for the cell. However, only recently, Russian experts have discovered a new function in these proteins: countering cancer.

Researchers from several Russian research institutes have found that phosphatases slow the growth of lung adenocarcinoma (a type of malignant tumor in non-small cell lung cancer), and cause cancer cells to age. We emphasize that the experiments were conducted on tissue cultures, that is, “in vitro.”

The retinoblastoma protein (protein name abbreviated pRb; gene name abbreviated RB or RB1) is a tumor suppressor protein that is dysfunctional in several major cancers. Rb belongs to the pocket protein family, whose members have a pocket for the functional binding of other proteins.

Russian scientists believe that the key is to help the Rb protein.  Phosphatases contribute to the production of active forms of this protein that can resist tumors. The retinoblastoma protein is a tumor suppressor protein that is dysfunctional in several major cancers.

One function of Rb is to prevent excessive cell growth by inhibiting cell cycle progression until a cell is ready to divide.

Scientists have found that the lack of these phosphatases can contribute to the development of cancer. The experiment showed that activation of a well-known group of oncogenes miR-96/182/183 leads to a decrease in the number of life-saving enzymes. It is natural to assume that this is due to the harmful effect of dangerous genes.

According to the World Health Organization, there are over 2 million cases of the lung cancer every year around the world. It is the number one type of cancer that affects the global population, and 85% of lung cancer cases are due to smoking.

The new work in the field would not have short turn around time, but will be a long term project. It is expected to be completed prior to 2030.

Only $1/click

Submit Your Ad Here

Christina Kitova

I spent most of my professional life in finance, insurance risk management litigation.

Leave a Reply